caa a22 4500 605491178 CHVBK 20210128100508.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s10147-014-0773-4 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0773-4 Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II clinical study [Elektronische Daten] [Haruyuki Takaki, Koichiro Yamakado, Masakatsu Tsurusaki, Taku Yasumoto, Yasutaka Baba, Yoshiaki Narimatsu, Masashi Shimohira, Masato Yamaguchi, Kunihiro Matsuo, Yoshitaka Inaba, Koji Mikami, Ryohei Watanabe, Norifumi Nishida, Hiroshi Anai, Hideaki Kakizawa, Shozo Hirota] Purpose: This single-arm, multicenter, phase-II trial evaluated the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) using fine-powder cisplatin and iodized-oil suspension in patients with intermediate- and advanced-stage [Barcelona Clinic Liver Cancer (BCLC) stage-B and stage-C] hepatocellular carcinomas (HCCs). Methods: The Institutional Review Board approved this study and patients provided written informed consent. Thirty-five patients (24 men and 11 women, mean 74±6years [range 60-87years]) with BCLC stage-B (57%, 20/35) or stage-C (43%, 15/35) HCCs who were not candidates for other locoregional treatments were enrolled. HAIC was performed using a suspension of fine-powder cisplatin with a maximum dose of 65mg/m2 and iodized oil on demand. The primary endpoint was the response rate evaluated based on Response Evaluation Criteria in Solid Tumor (RECIST) and modified RECIST (mRECIST). Secondary endpoints were overall survival, progression-free survival, and safety. Results: The initial and best overall response rates at 4weeks and 3months, respectively, were 14 and 17% based on RECIST, and 57 and 23% based on mRECIST. The median overall and progression-free survival times were 18 and 4months, respectively. The most frequent grade-3 or grade-4 adverse events were elevation of serum alanine (23%) and aspartate aminotransferase (20%), and thrombocytopenia (17%). Conclusion: This HAIC provides promising therapeutic effects with acceptable safety to patients with intermediate-stage and advanced-stage HCCs. Japan Society of Clinical Oncology, 2014 Hepatic arterial infusion chemotherapy nationallicence Fine-powder cisplatin nationallicence Iodized oil nationallicence Hepatocellular carcinomas nationallicence Takaki Haruyuki Department of Radiology, Mie University School of Medicine, Mie, Japan aut Yamakado Koichiro Department of Radiology, Mie University School of Medicine, Mie, Japan aut Tsurusaki Masakatsu Department of Radiology, Shimane University Faculty of Medicine, Izumo, Japan aut Yasumoto Taku Department of Radiology, Toyonaka Municipal Hospital, Toyonaka, Japan aut Baba Yasutaka Department of Radiology, Kagoshima University, Kagoshima, Japan aut Narimatsu Yoshiaki Department of Radiology, Kawasaki Municipal Hospital, Kawasaki, Japan aut Shimohira Masashi Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan aut Yamaguchi Masato Center for Endovascular Therapy, Kobe University Graduate School of Medicine, Kobe, Japan aut Matsuo Kunihiro Department of Radiology, Narumi Hospital, Hirosaki, Japan aut Inaba Yoshitaka Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan aut Mikami Koji Department of Radiology, Suita Municipal Hospital, Suita, Japan aut Watanabe Ryohei Department of Surgery, Matsuyama Shimin Hospital, Matsuyama, Japan aut Nishida Norifumi Department of Radiology, Osaka City University Graduate School of Medicine, Osaka, Japan aut Anai Hiroshi Department of Radiology, Nara Medical University, Kashiwara, Japan aut Kakizawa Hideaki Department of Diagnostic Radiology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan aut Hirota Shozo Department of Radiology, Hyogo College of Medicine, Nishinomiya, Japan aut International Journal of Clinical Oncology Springer Japan 20/4(2015-08-01), 745-754 1341-9625 20:4<745 2015 20 10147 https://doi.org/10.1007/s10147-014-0773-4 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0773-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Takaki Haruyuki Department of Radiology, Mie University School of Medicine, Mie, Japan aut NATIONALLICENCE 700 1- Yamakado Koichiro Department of Radiology, Mie University School of Medicine, Mie, Japan aut NATIONALLICENCE 700 1- Tsurusaki Masakatsu Department of Radiology, Shimane University Faculty of Medicine, Izumo, Japan aut NATIONALLICENCE 700 1- Yasumoto Taku Department of Radiology, Toyonaka Municipal Hospital, Toyonaka, Japan aut NATIONALLICENCE 700 1- Baba Yasutaka Department of Radiology, Kagoshima University, Kagoshima, Japan aut NATIONALLICENCE 700 1- Narimatsu Yoshiaki Department of Radiology, Kawasaki Municipal Hospital, Kawasaki, Japan aut NATIONALLICENCE 700 1- Shimohira Masashi Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan aut NATIONALLICENCE 700 1- Yamaguchi Masato Center for Endovascular Therapy, Kobe University Graduate School of Medicine, Kobe, Japan aut NATIONALLICENCE 700 1- Matsuo Kunihiro Department of Radiology, Narumi Hospital, Hirosaki, Japan aut NATIONALLICENCE 700 1- Inaba Yoshitaka Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan aut NATIONALLICENCE 700 1- Mikami Koji Department of Radiology, Suita Municipal Hospital, Suita, Japan aut NATIONALLICENCE 700 1- Watanabe Ryohei Department of Surgery, Matsuyama Shimin Hospital, Matsuyama, Japan aut NATIONALLICENCE 700 1- Nishida Norifumi Department of Radiology, Osaka City University Graduate School of Medicine, Osaka, Japan aut NATIONALLICENCE 700 1- Anai Hiroshi Department of Radiology, Nara Medical University, Kashiwara, Japan aut NATIONALLICENCE 700 1- Kakizawa Hideaki Department of Diagnostic Radiology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan aut NATIONALLICENCE 700 1- Hirota Shozo Department of Radiology, Hyogo College of Medicine, Nishinomiya, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/4(2015-08-01), 745-754 1341-9625 20:4<745 2015 20 10147